Vanguard Group
PMCB icon

Vanguard Group’s PharmaCyte Biotech PMCB Stock Holding History

Vanguard Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$54.2K Hold
74,919
– – ﹤0.01% 4234
2025
Q3 		$72.7K Sell
74,919
-119,528
-61% -$119K ﹤0.01% 4258
2025
Q2 		$214K Sell
194,447
-71
-0% -$79 ﹤0.01% 4080
2025
Q1 		$243K Buy
194,518
+2,131
+1% +$3.46K ﹤0.01% 4031
2024
Q4 		$298K Hold
192,387
– – ﹤0.01% 4041
2024
Q3 		$367K Hold
192,387
– – ﹤0.01% 4044
2024
Q2 		$377K Buy
192,387
+17,785
+10% +$38.3K ﹤0.01% 4068
2024
Q1 		$414K Buy
174,602
+3,267
+2% +$7.07K ﹤0.01% 4062
2023
Q4 		$370K Buy
171,335
+2,414
+1% +$5.23K ﹤0.01% 4116
2023
Q3 		$355K Sell
168,921
-14,661
-8% -$37.4K ﹤0.01% 4151
2023
Q2 		$525K Sell
183,582
-517,868
-74% -$1.55M ﹤0.01% 4110
2023
Q1 		$2.04M Buy
701,450
+46,933
+7% +$138K ﹤0.01% 3664
2022
Q4 		$1.92M Buy
654,517
+11,343
+2% +$32.5K ﹤0.01% 3669
2022
Q3 		$1.54M Buy
643,174
+800
+0.1% +$2.02K ﹤0.01% 3853
2022
Q2 		$1.44M Buy
642,374
+27,749
+5% +$60.6K ﹤0.01% 3955
2022
Q1 		$1.41M Buy
614,625
+959
+0.2% +$2.13K ﹤0.01% 4096
2021
Q4 		$1.53M Buy
+613,666
New +$1.69M ﹤0.01% 4133

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vanguard Group's PMCB Position: Q4 2025 in Review

Vanguard Group held its PharmaCyte Biotech (PMCB) position steady in Q4 2025 at 74,919 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

Vanguard Group first reported a position in PMCB in Q4 2021 and has held it in 17 quarters since. The position peaked at $2.04M in Q1 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q4 2025.

  • Vanguard Group held 74,919 shares of PharmaCyte Biotech worth $54.2K as of Q4 2025.
  • Vanguard Group left its PharmaCyte Biotech share count unchanged in Q4 2025.
  • PharmaCyte Biotech made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4234 holding.
  • Vanguard Group first reported a position in PharmaCyte Biotech in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's PharmaCyte Biotech position peaked at $2.04M in Q1 2023.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.